A Medical Device Daily
U.S. Preventive Medicine (Dallas) and deCode Genetics (ReykJavik, Iceland) reported signing a letter of intent to add genetic testing to expand both companies' personalized medicine services in the U.S. and internationally.
"The signing of the letter of intent with deCode is significant because we will be the first entity in the U.S. and internationally to offer a full continuum of geographically dispersed, comprehensive solutions for personalized medicine including preventive care, wellness and disease management," said Christopher Fey, CEO and chairman of U.S. Preventive Medicine. "Our consumer, employer and physician customers will now be able to take advantage of a wide range of innovative personalized medicine services, including an opt-in genetic testing program for clients of our Centers for Preventive Medicine and members of The Prevention Plan."
He added, "Our goal is to make the most advanced prevention strategies — including more precise risk stratification — available to informed consumers who want to use the best medicine has to offer to enjoy more good years."
Fey said U.S. Preventive Medicine's expansion into personalized medicine is the next step in the company's plan to "provide practical solutions at every point in the healthcare continuum," both nationally and internationally.
deCODE is a biopharmaceutical company.